Table of Contents
Insight Pharma Reports’ Gene Therapy: Moving Toward Commercialization”, outlines the progress of the gene therapy field since its inception in the 1970s, with a special focus on clinical-stage gene therapy programs that are aimed at commercialization, and the companies that are carrying out these programs. A major theme of this report is whether gene therapy can attain commercial success by the early-to-mid 2020s, which types of gene therapy programs have the greatest likelihood of success, and what hurdles might stand in the way of clinical and commercial success of leading gene therapy programs.
In accord with the focus of this report, we have been asking:
Whether gene therapy can attain commercial success by the early-to-mid 2020s,
Which types of gene therapy programs have the greatest likelihood of success,
What hurdles might stand in the way of clinical and commercial success of leading gene therapy programs.
In addition to chapters that focus on various areas of commercial gene therapy, this report includes:
An expert interview with Sam Wadsworth, Ph.D., the Chief Scientific Officer of Dimension Therapeutics and former Head of Gene Therapy R&D at Genzyme.
Survey data from 88 researchers involved in gene therapy
Companies profiled: uniQure, Voyager Therapeutics, Oxford BioMedica, GeneQuine Therapeutics, Celladon Corporation, and bluebird
Development of improved vectors (integrating and non-integrating vectors)
Gene therapy for ophthalmological diseases
Gene therapy for other rare diseases
Clinical-stage gene therapies for selected rare diseases other than hemophilias
Gene therapy for more common diseases
Companies whose central technology platform involves ex vivo gene therapy
CAR T-cell immunotherapy as an area of ex vivo gene therapy
Gene editing technology
Outlook for gene therapy
Market outlook for eight gene therapy products
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
Summary The Global Gene Therapy Partnering Terms and Agreements 2010-2017 report provides comprehensive understanding and unprecedented access to the gene therapy partnering deals and agreements entered ...
INTRODUCTION The concept of immunotherapies dates back to the 18th century; however, since inception, the field has evolved tremendously and is currently cited as one of the most rapidly growing segments ...
This study covers the world outlook for gene therapy across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the ...